Diagnostic approach in parenchymal lung diseases: Transbronchial lung biopsy? Cryobiopsy?

A. Kadri Çırak, Nuran Katgı, Onur F. Erer, Pınar Çimen, F. Fevziye Tuksavul, Burçin Hakoğlu.
Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey

**Background/Aim:** Diagnosis of interstitial lung diseases requires a multidisciplinary approach and a gold standard for histological diagnosis is open lung biopsy. Transbronchial lung biopsy (TBLB) and in recent years an alternative method cryobiopsy (TBLC) are used for the diagnosis of parenchymal lung lesions. The aim of this study is to compare the efficacy of concomitant conventional TBLB and TBLC.

**Materials and methods:** A total of 82 patients who underwent TBLC for diagnosis of diffuse parenchymal lung diseases at Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital between 2015 and 2018 were screened retrospectively and included in the study. 53.7% (n:44) of the patients were male, and 46.4% (n:38) of them were female. The mean age was 58.37 (±9.33) years. First TBLB and then TBLC were performed to all patients in the same session and their diagnostic performance was compared.
Results: Although both procedures were done in the same session 45 patients (54.9%) were diagnosed with TBLB and 75 patients (91.5%) were diagnosed with TBLC (p < 0.001). Hemorrhage was observed in 39 patients (47.6%), but only one had a massive hemorrhage. Pneumothorax was observed in 6 patients (7.3%) and none of them required tube drainage.

Conclusion: Transbronchial lung cryobiopsy is a promising technique for the diagnosis of parenchymal lung diseases compared to transbronchial lung biopsy.

Key Words: Transbronchial lung biopsy, transbronchial lung cryobiopsy, parenchymal lung disease.

1. Introduction

Diagnosis of interstitial lung diseases (ILD) requires a multidisciplinary approach and the gold standard for histological diagnosis is surgical lung biopsy (SLB). Bronchoscopy is the most commonly used diagnostic tool in lung lesions. The diagnostic success of conventional transbronchial lung biopsy (TBLB) has varied between various parenchymal lung diseases, and its use as an alternative diagnostic tool has increased in recent years due to the use of cryoprobes with adequate sampling and low rate of side effects.

ILD is a heterogeneous group consisting of more than 200 different disorders, requiring a multidisciplinary approach for diagnosis. Invasive procedures such as bronchoscopic procedures and open lung biopsy are often required for the diagnosis (1,2). Idiopathic pulmonary fibrosis
(IPF), also known as usual interstitial pneumonia (UIP), is a chronic, progressive and fibrotic ILD. Although the etiology of IPF is unknown, it has a characteristical image and histological pattern. IPF has a very poor prognosis and the median survival rate is 3 years (3). Since they are frequently confused with diseases such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD), patients lose their time by following these diagnoses. Because of the short survival time early diagnosis has a vital role (4). While half of the patients with IPF are diagnosed radiologically, tissue biopsy is required for the diagnosis of the other half. Correct diagnosis must be made for a better treatment and prognosis (5).

In the mid-1960s, TBLB was used for the diagnosis of diffuse parenchymal lung diseases (6,7). Although conventional TBLB provides the diagnosis of sarcoidosis, neoplasia, some infections and cryptogenic organized pneumonia (COP), in most cases the diagnosis cannot be reached due to the small samples and the crush artifact of the biopsy material (8-10). In patients with ILD, although the samples taken with conventional TBLB are evaluated together with clinical and radiological findings, only 20-30% of patients are truly diagnosed (11).

Cryoprobe were first used in bronchoscopy in 1977 (12). Transbronchial lung biopsy with cryoprobe (TBLC) is a relatively recent technique for lung parenchyma sampling (13). After the tissue specimen is taken, the bronchoscope and cryoprobe removed together, and this provides an advantage in avoiding crush artifacts (14). TBLC specimens are better in quality because they are larger in size and contain no artifact compared with TBLB, so the diagnosis rate is higher (13-15). The disadvantage of this technique is that it is closer to surgical technique and it should be performed under general anesthesia and needs tracheal intubation (5,16,17).
We planned this study to see how the TBLC increases the chance to diagnose the diffuse parenchymal lung diseases comparing to TBLB.

2. Materials and methods

A total of 82 patients who underwent TBLC for diagnosis of diffuse parenchymal lung diseases at Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital between 2015 and 2018 were screened retrospectively and included in the study. 53.7% (n:44) of the patients were male, and 46.4% (n:38) of them were female. The mean age was 58.37 (±9.33) years. All these patients were suspected of having ILD, but could not be diagnosed with history, physical examination, laboratory tests, and high resolution computed tomography (HRCT) of the thorax. All patients were older than 18 years. None of them had coagulopathy, pulmonary hypertension, and severe cardiac disease. All patients were informed about the procedure and written informed consent was obtained from all patients. All bronchoscopies were performed by pulmonologists. The study was approved by the local ethics committee (07/11/2018 – 8566).

The procedure was performed in the operating room. Oxygen saturation, blood pressure, electrocardiogram, and transcutaneous partial carbon dioxide pressure were monitored during the procedure. Accompanied by an anesthesiologist, all patients were intubated with a rigid bronchoscope (Dutau-Novatech, Bronchial Tube size 12, black, 10.7 mm working canal, 35 cm length) by providing deep sedation with midazolam, fentanyl
citrate, and propofol. The flexible bronchoscope (Olympus CV 170, with a diameter of 2.8 mm) was passed through the rigid bronchoscope. Before the procedure, TBLB was performed with fluoroscopy guidance from the target area which was identified by the radiologist. The balloon (Broncho Dilator Balloon Catheter) was then placed in the target segment through the rigid bronchoscope. Cryoprobe (Erbolryo CA, ERBE, 2.4 mm in diameter, 900 mm length) was sent to the same segment through a flexible bronchoscope. It was advanced to a distance of 10-20 mm to the chest wall with the guidance of fluoroscopy. Cooling with N₂O was carried out for 3 to 6 seconds. After freezing, a flexible bronchoscope was removed with the cryoprobe. The sample was kept in saline solution and a formalin solution was used for fixation. The balloon was inflated immediately after TBLC was removed. The procedure was repeated 2 to 5 times.

Bleeding is defined as ‘‘mild’’ if it is less than 10 ml and that is controlled by endoscopic aspiration, ‘‘moderate’’ if it is 10-40 ml that requires bronchial occlusion and/or cold saline infusion, and ‘‘severe’’ if it is more than 40 ml that requires transfusion, surgical interventions and needs intensive care unit admission. After bleeding control, sedation was stopped and patients were extubated. After the procedure, the patients were kept under close observation in the intensive care unit for 2 hours. After 4 hours, pneumothorax control was performed by chest radiography.

Clinical information, radiological findings, histopathological results were then reviewed by clinicians, radiologist and pathologists and a multidisciplinary diagnosis was made.

**Statistical analysis**
The age of patients was presented as mean standard deviation, while all other qualitative variables were presented as frequency and percentage. The comparison between the two biopsy procedures was analyzed with McNemar test. The relationship between the diagnostic yield with the size and number of biopsies was investigated with Linear-by-Linear Association test. All statistical analysis was performed with the statistical package (SPSS Inc., version 25.0), and the level of significance was predetermined as 0.05.

3. Results

62.2% had diffuse radiological involvement and 37.8% of them had localized involvement. In the same session before the TBLC procedure, all patients underwent TBLB with scopy from the most affected area. Most of the biopsies (63.4%) were taken from the right lower lobe (Table 1). The mean number of biopsies was 3, while the mean biopsy size was 2-3 mm. There was no relationship between the number of biopsies and diagnosis rate, and the size of specimen and diagnosis rate.

Overall, a specific pathological diagnosis was revealed in 75/82 (91.5%) in TBLC cases while 45/82 (54.9%) in TBLB cases (p<0.001). UIP was the most common disease (21 patients) in the TBLC group. Only one patient was diagnosed as UIP in TBLB group, although the procedure was performed under scopy. Hypersensitivity pneumonitis (HSP) were detected in 11 cases by TBLC, and two HSP were detected by TBLB. 10 organizing
pneumonia (OP) were detected by TBLC and 7 by TBLB. 6 non-specific interstitial pneumonia (NSIP) by TBLC, and 2 by TBLB, 3 primary lung cancer and one by TBLB, 2 lung metastases. All the pathological diagnosis detected are shown in Table 2.

Safety outcomes are summarized in Table 3. Complications were observed in 45 of the 82 patients included in the study. In 39 (47.6%) patients, bleeding was observed during the procedure, 23 of them had mild and 15 of them had moderate bleeding. One patient had severe bleeding requiring temporary intubation and controlled with supportive therapy. Pneumothorax occurred in 6 (7.3%) patients that didn't require chest-tube drainage.

4. Discussion

In this study, TBLB and TBLC were performed for all patients in the same session for diagnostic purposes, and their diagnostic performance was compared. As a result, the rate of diagnosis was found to be much higher in patients who underwent TBLC.

Diagnosis of ILD requires a multidisciplinary approach of pulmonology, radiology and pathology departments. Histopathological diagnosis is necessary if the clinical and laboratory findings suggest ILD, but the differential diagnosis cannot be made by radiological features. SLB is the gold standard for the diagnosis of ILD (1). However, TBLB is often preferred than SLB in daily practice because of its high complications and high cost (18). On the other hand, the alveolar parenchymal tissue is not
adequately monitored or can be non-diagnostic because of the biopsy sample taken with TBLB is too small and contains crush artifacts, and that reduces the diagnostic efficiency (19). In recent years, the larger biopsy specimen was taken with TBLC and does not contain crush artifacts, and since it is performed in the presence of scopy-guided biopsy from the area of the lesions the diagnosis rate is increased (13,15). The disadvantages are that it is technically similar to the surgical procedure because it is performed in the operating room and under general anesthesia, and complications such as pneumothorax and bleeding are slightly higher than TBLB (1,5,16).

In this study we demonstrated better diagnostic performance with TBLC, and this created an advantage in interstitial lung diseases that were difficult to diagnose. The complications were observed in 45 (54.9%) of 82 patients. The most common complication was bleeding during the procedure in 39 (47.6%) patients. Of these, 23 (28%) were mild, 15 (18.3%) were moderate and 1 (1.2%) had severe bleeding. No treatment required for mild bleeding, moderate bleeding was controlled with cold saline solution, bronchial blockers, and Fogarty balloon. The patient with severe bleeding was required intubation and needed a transfusion and monitored in the intensive care unit for two days. No cases of fatal bleeding were observed.

In our study, the bleeding complication rates in the TBLC-treated group were significantly lower than those reported by Hetzel et al. (61.8% mild bleeding, 18.2%
severe bleeding) and another study of Pajares et al. (30.8% mild, 56.4% moderate bleeding) (15,19). We observed that our bleeding complication rates decreased as our procedure experience increased.

Another complication of the TBLC procedure is pneumothorax, and its rate is variable in the literature ranging from 1% to 30%. Pneumothorax without tube drainage was detected in 6 (7.3%) of our patients. These rates of pneumothorax were very close to those reported in the literature. Among these studies, this rate was found to be 7.7% in Pajares et al. and 4.95% in Gershmann et al study (15,20).

The diagnostic efficiency of TBLC is considerably higher than that of TBLB because the TBLC procedure allows larger tissue samples to be taken (13,15).

In our patient group, the maximum number of biopsies performed in the same procedure as TBLC was 5 (mean 3) and the largest of the samples was 8mm (mean 2-3 mm).

The samples taken with TBLB were found to be so small that the pathology physicians could not determine the size. As expected, the tissue samples obtained in the TBLC arm were much larger and the diagnosis rate of the procedure was much higher. 37 (45.1%) nondiagnostic materials were observed in TBLB arm compared to 7 (8.5%) nondiagnostic materials in TBLC arm.

Of the 82 patients, 21 were diagnosed with Usual Interstitial Pneumonia (UIP) with TBLC, while this number was only 1 with TBLB. We have seen that almost all of these patients who are rapidly progressing and whose treatment should be started as soon as possible can be missed with TBLB. The second most common diagnosis was HSP and
11 of them diagnosed with TBLC, and two of them with TBLB. Although there are not many studies comparing TBLB and TBLC in the literature, Bango-Alvarez A et al. reported 22 UIP, 10 OP, 11 NSIP and 12 silicosis diagnoses in their study involving 106 patients (21). In the study of Ramaswamy et al. four of ten ILD patients diagnosed with TBLB, and seven with TBLC (22). Casoni and colleagues diagnosed 47 of 69 patients with UIP, 9 with NSIP, 2 with desquamative interstitial pneumonia, one with OP, one with eosinophilic pneumonia, one with diffuse alveolar damage, one with HSP and one with follicular bronchiolitis with TBLC.

Although we explained the superiority of TBLC to the TBLB because of the larger biopsy size, we could not detect a statistically significant difference between the size of the tissue and the number of biopsies taken by TBLC in our study. We attribute this to the fact that the groups that make up the number and size of the biopsy were not numerically close to each other and that TBLC was still more effective than TBLB, and that the crush artifact was not observed in TBLC.

In conclusion our study demonstrated higher diagnostic yield with TBLC compared to TBLB. The limitation of our study it was retrospective. In the same session first TBLB and then TBLC were performed, so the complications could not be compared.
References

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788-824.

2. Poletti V, Ravaglia C, Gurioli C, Piciucchi S, Dubini S, et al. Invasive diagnostic techniques in idiopathic interstitial pneumonias. Respirology. 2016; 21(1): 44–50.

3. Strongman H, Kausar I, Maher TM. Incidence, prevalence and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv. Ther. 2018; 35(5): 724–736.

4. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, et al. Delayed access and survival in idiopathic pulmonary fibrosis: A cohort study. Am. J. Respir. Crit. Care Med. 2011; 184(7): 842–847.

5. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014; 9(2): e86716.

6. Andersen HA, Fontana RS, Harrison EG Jr. Transbronchoscopic lung biopsy for diffuse pulmonary diseases. Dis Chest 1965; 48(2): 187–192.

7. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
8. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch Da, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188(6): 733–748.

9. Xaubet A, Ancochea J, Bollo E, Fernandez-Fabrellas E, Franquet T, et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol 2013; 49(8): 343–353.

10. Sheth JS, Belperio JA, Fishbein MC, Kazerooni EA, Lagstein A, et al. Utility of transbronchial vs surgical lung biopsy in the diagnosis of suspected fibrotic interstitial lung disease. Chest 2017; 151(2): 389-399.

11. Kebbe J, Abdo T. Interstitial lung disease: the diagnostic role of bronchoscopy. J Thorac Dis. 2017; 9(10): 996–1010.

12. Raparia K, Aisner DL, Allen TC, Beasley MB, Borczuk A, et al. Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med. 2016; 140(11): 1281-1284.

13. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration 2009; 78(2): 203-208.

14. Colby TV, Tomassetti S, Cavazza A, Dubini A, Poletti V. Transbronchial cryobiopsy in diffuse lung disease: update for the pathologist. Arch Pathol Lab Med. 2017; 141(7): 891-900.
15. Pajares V, Puzo C, Castillo D, Lerma E, Montero MA, et al. Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: a randomized trial. Respirology 2014; 19(6): 900–906.

16. Pajares V, Torrego A, Puzo C, Lerma E, Gil De Bernabe MA, et al. Transbronchial lung biopsy using cryoprobes. Arch Bronconeumol 2010; 46(3): 111–115.

17. Hernández-González F, Lucena CM, Ramírez J, Sanchez M, Jimenez MJ, et al. Cryobiopsy in the diagnosis of diffuse interstitial lung disease: yield and cost-effectiveness analysis. Arch Bronconeumol 2015; 51(6): 261–267.

18. Ganganah O, Guo SL, Chiniah M, Li YS. Efficacy and safety of cryobiopsy versus forceps biopsy for interstitial lung diseases and lung tumours: A systematic review and meta-analysis. Respirology 2016; 21(5): 834-841.

19. Hetzel J, Eberhardt R, Herth FJ, Petermann C, Reichle G, et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J. 2012; 39(3): 685-690.
20. Gershman E, Fruchter O, Benjamin F, Nader AR, Rosenqarten D, et al. Safety of Cryo-Transbronchial Biopsy in Diffuse Lung Diseases: Analysis of Three Hundred Cases. Respiration 2015; 90(1): 40-46.

21. Bango-Alvarez A, Ariza-Porta M, Torres-Rivas H, Fernandez-Fernandez L, Prieto A et al. Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases - how to do it. ERJ Open Res. 2017; 3(1): 00148-2016.

22. Ramaswamy A, Homer R, Killam J, Pisani M, Murphy M et al. Comparison of transbronchial and cryobiopsies in evaluation of diffuse parenchymal lung disease. J Bronchology Interv Pulmonol. 2016 January ; 23(1): 14–21.
Table 1. The lung biopsy regions

| Biopsy regions                          | %  |
|----------------------------------------|----|
| Right lower lobe                       | 63.4 |
| Left lower lobe                        | 24.4 |
| Right upper lobe                       | 8.5  |
| Right upper and lower lobe             | 1.2  |
| Left upper lobe                        | 1.1  |
| Left upper and lower lobe              | 1.1  |

Table 3. Diagnosis rates with TBLB and TBLC

| Diagnosis                  | TBLB n(%) | TBLC n (%) |
|----------------------------|-----------|------------|
| IPF                        | 1 (1.2)   | 21 (25.6)  |
| Nonspecific changes        | 16 (19.5) | 13 (15.9)  |
| Diagnosis                  | First Column | Second Column |
|----------------------------|--------------|---------------|
| HSP                        | 2 (2.4)      | 11 (13.4)     |
| OP                         | 7 (8.5)      | 10 (12.2)     |
| Nondiagnostic              | 37 (45.1)    | 7 (8.5)       |
| NSIP                       | 2 (2.4)      | 6 (7.3)       |
| Lung cancer                | 1 (1.2)      | 3 (3.7)       |
| Unclassified ILD           | 0 (0)        | 2 (2.4)       |
| Sarcoidosis                | 1 (1.2)      | 2 (2.4)       |
| Metastases                 | 2 (2.4)      | 2 (2.4)       |
| Normal Lung Tissue         | 1 (1.2)      | 2 (2.4)       |
| Follicular bronchiolit     | 1 (1.2)      | 1 (1.2)       |
| Churge Strauss             | 0 (0)        | 1 (1.2)       |
| Pneumoconiosis             | 1 (1.2)      | 1 (1.2)       |
Table 4. Complications of the patients

| Complications   | n (%)  |
|-----------------|--------|
| 1. Bleeding     |        |
|                 |        |
| a. Mild         | 23 (28.04) |
| b. Moderate     | 15 (18.29) |
| c. Severe       | 1 (1.21) |
| 2. Pneumothorax | 6 (7.3)  |